PD-1抗体治疗肝门部胆管癌复发一例-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

PD-1抗体治疗肝门部胆管癌复发一例

A case of recurrence of hilar cholangiocarcinoma treated with PD-1 antibody

ES评分 0 浏览量：785 下载量：0

DOI	10.12208/j.ijcr.20220028
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2022, 6(1)
作者	谭元灿,张治清*,杨洪,郭鹏,别平,
作者单位	重庆医科大学附属第三医院肝胆胰外科重庆 ;
摘要	患者男性，因肝门部胆管癌于2019年3月22日在我院行右半肝切除+胆肠吻合术。术后患者规律化疗9次因不能耐受停止化疗，术后6个月复查显示肝内多发转移灶。因患者不能耐受化疗，遂予以PD-1抗体（信迪利单抗注射液）治疗，4周期后复查显示肝内病灶明显减少，胆肠吻合口占位消失、胆红素及肝功能几乎恢复正常。
Abstract	The male patient underwent right hepatectomy + cholangioenterostomy in our hospital on March 22, 2019 due to hilar cholangiocarcinoma. The patient stopped chemotherapy for 9 times of regular chemotherapy after surgery because of intolerance, and the follow-up 6 months after surgery showed multiple intrahepatic metastases. Because the patient could not tolerate chemotherapy, he was treated with PD-1 antibody (sintilimab injection). After 4 cycles, the re-examination showed that the intrahepatic lesions were significantly reduced, the biliary-enteric anastomotic stoma disappeared, and the bilirubin and liver function were almost the same. Back to normal.
关键词	胆管恶性肿瘤；黄疸；PD-1抗体
KeyWord	Malignant Tumor of Bile Duct; Jaundice; PD-1 Antibody
基金项目
页码	163-166

参考文献
相关文献

[1] Benson AB, D'Angelica MI, Abbott DE, et al. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. J Natl Compr Canc Netw[J]. 2019;17(4):302-310. doi:10.6004/jnccn.2019.0019

[2] 隋明昊，卢实春.PD-1抗体治疗肝内胆管细胞癌术后复发一例[J].中华肝胆外科杂志，2019,25（2）：144-146.

[3] Chen WX, Li GX, Hu ZN, etal. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review. Medicine (Baltimore) [J]. 2019;98(45):e17832.doi:10.1097/MD.0000000000017832

[4] 何珊，黄银久，闵静婷等.肝内胆管细胞癌组织中 PD － L1 表达及与临床病理特征的关系.现代肿瘤医学,2020.28(15):2663-2666.

[5] Ma K, Wei X, Dong D, Wu, et al. PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncol Lett. 2017;14(1):250-256. doi:10.3892/ol.2017.6105。

[6] Mody K, Starr J, Saul M, et al. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. J Gastrointest Oncol. 2019;10(6):1099-1109.doi:10.21037/jgo.2019.08.08

[7] 王毅欣，胡宗涛，张永康等.PD-1治疗晚期原发性肝癌患者的安全性及临床疗效观察[J].肿瘤防治研究，2020.47（4）：298-302.

引用本文

谭元灿,张治清*,杨洪,郭鹏,别平. PD-1抗体治疗肝门部胆管癌复发一例 [J]. 国际临床研究杂志. 2022; 6; (1). 163 - 166.

文献评论

相关学者

相关机构